Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy

Yu Guo; Zhiqiang Wu; Shunli Shen; Ruomi Guo; Jing Wang; Weiwei Wang; Kun Zhao; Ming Kuang; Xintao Shuai

doi:10.1038/s41467-018-05764-7

Nature Communications (Aug 2018)

Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy

Yu Guo,
Zhiqiang Wu,
Shunli Shen,
Ruomi Guo,
Jing Wang,
Weiwei Wang,
Kun Zhao,
Ming Kuang,
Xintao Shuai

Affiliations

Yu Guo: Cancer Center & Precision Medicine Institute, the First Affiliated Hospital of Sun Yat-Sen University
Zhiqiang Wu: Cancer Center & Precision Medicine Institute, the First Affiliated Hospital of Sun Yat-Sen University
Shunli Shen: Cancer Center & Precision Medicine Institute, the First Affiliated Hospital of Sun Yat-Sen University
Ruomi Guo: Department of Radiology, the Third Affiliated Hospital of Sun Yat-Sen University
Jing Wang: Cancer Center & Precision Medicine Institute, the First Affiliated Hospital of Sun Yat-Sen University
Weiwei Wang: School of Materials Science and Engineering of Sun Yat-Sen University
Kun Zhao: Cancer Center & Precision Medicine Institute, the First Affiliated Hospital of Sun Yat-Sen University
Ming Kuang: Cancer Center & Precision Medicine Institute, the First Affiliated Hospital of Sun Yat-Sen University
Xintao Shuai: Cancer Center & Precision Medicine Institute, the First Affiliated Hospital of Sun Yat-Sen University

DOI: https://doi.org/10.1038/s41467-018-05764-7
Journal volume & issue: Vol. 9, no. 1
pp. 1 – 16

Abstract

Read online

Novel therapeutic strategies are needed to improve the treatment outcome of hepatocellular carcinoma. Here, the authors develop a theranostical targeted nanomedicine platform that reveals the key oncogenic role of PBOV1 in hepatocellular carcinoma.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal